CSIMarket
 
Pasithea Therapeutics Corp   (KTTA)
Other Ticker:  
 
 
Price: $6.9733 $-0.23 -3.149%
Day's High: $7 Week Perf: -7.02 %
Day's Low: $ 6.97 30 Day Perf: 7.53 %
Volume (M): 1 52 Wk High: $ 17.40
Volume (M$): $ 6 52 Wk Avg: $8.43
Open: $7.00 52 Wk Low: $5.25



 Market Capitalization (Millions $) 9
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -16
 Cash Flow (TTM) (Millions $) -23
 Capital Exp. (TTM) (Millions $) 2

Pasithea Therapeutics Corp
Pasithea Therapeutics Corp is a pharmaceutical company that focuses on developing novel therapeutics for the treatment of sleep disorders and mental health conditions. The company aims to improve patient outcomes and quality of life by addressing unmet needs in these areas. With a combination of innovative science and cutting-edge technology, Pasithea Therapeutics Corp is dedicated to advancing the field of sleep and mental health therapeutics.


   Company Address: 1111 Lincoln Road Miami Beach 33139 FL
   Company Phone Number: 514-4174   Stock Exchange / Ticker: NASDAQ KTTA
   KTTA is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Pasithea Therapeutics Initiates Phase 1 Clinical Trials in the US: Paving the Way for Groundbreaking MEK Inhibitor

Published Tue, Feb 13 2024 12:59 PM UTC

Pasithea Therapeutics, a prominent biopharmaceutical company known for innovative drug development, has recently announced the commencement of Phase 1 trials for two of its cutting-edge products. The first trial involves the administration of PAS-004, while the second trial focuses on evaluating the safety, efficacy, and biomarker data of the company's next-generation MEK in...

Product Service News

Pasithea Therapeutics' Novel MEK Inhibitor, PAS-004, Receives Green Light from FDA for Advanced Cancer Trials

Published Tue, Jan 2 2024 1:35 PM UTC

Pasithea Therapeutics, a leading biopharmaceutical company, recently achieved a significant milestone as the U.S. Food and Drug Administration (FDA) approved their Investigational New Drug (IND) application for PAS-004, a novel MEK inhibitor. The IND approval allows Pasithea to commence Phase 1 trials in advanced cancer patients, starting in the first quarter of 2024, with p...

Clinical Study

Breaking New Grounds: Pasithea's PAS-004 Shows Promise in Battle Against NRAS mutation Cancer

Published Mon, Dec 11 2023 1:01 PM UTC


Highly innovative biopharmaceutical company Pasithea Therapeutics, listed on the Nasdaq as KTTA, has recently divulged promising news concerning its leading-edge research on PAS-004. In what stands as a major stepping-stone ahead of its proposed Phase I, in-human trials slated for the first quarter of 2024, the firm has reported positive in vivo preclinical efficacy dat...

Management Announcement

Pasithea Therapeutics Reports Positive Pre-IND Meeting Outcome but Faces Financial Struggles with a Negative ROI

Published Wed, Nov 29 2023 12:59 PM UTC

Pasithea Therapeutics Faces Financial Challenges Amid Positive Clinical Development Outcome
Pasithea Therapeutics Corp, a healthcare company specializing in MEK inhibitor development, recently announced the outcome of its Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the clinical development of its PAS-004 drug. Des...

Pasithea Therapeutics Corp

Major Pharmaceutical Preparations Company Maintains Steady Revenue: A Year-on-Year Comparison Ending September 30, 2023

The stock market can be a rollercoaster ride for investors, with ups and downs that can cause anxiety and uncertainty. However, amidst all the volatility, there are success stories that remind us of the potential for growth and profitability. One such success story is Pasithea Therapeutics Corp, a company that has recently shown promising signs of improvement.
In the financial span closing September 30, 2023, Pasithea Therapeutics Corp reported a loss of -$0.14 per share, which is a significant improvement compared to the -$0.17 loss per share from the previous year. Not only that, but the company managed to grow its deficit from -$0.01 per share in the prior reporting period. These figures indicate a positive trend for Pasithea, demonstrating their dedication to financial progress and stability.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com